Complementary adenoviral vectors for oncolysis

Cancer Gene Therapy

Volumn 6, Issue 1, 1999, Pages 21-25

  Alemany, Ramon ^a,c   Lai, Shoupeng ^b   Lou, Yan Chun ^c,d   Jan, Hsing Yi ^c,d   Fang, Xiangming ^c,d   Zhang, Wei Wei ^c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b GENVEC INC   (United States)

^c GenStar Therapeutics Corporation   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Adenoviruses; Cancer; Oncolysis; Replicating vectors; Virotherapy

Indexed keywords

ALPHA FETOPROTEIN; GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN;

ADENOCARCINOMA; ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; DOSE RESPONSE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LIVER CELL CARCINOMA; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; TIME;

ADENOCARCINOMA; ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, SCID; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032616156     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700001     Document Type: Article

References (15)

1. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology. 1993; 36:193-214.
2. Russell SJ. Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol. 1994;5:437-443.
3. Yazaki T, Manz JH, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replicationcompetent multimutated herpes simplex virus 1. Cancer Res. 1995;55:4752-4756.
4. Bischof JR, Kirn DH, Williams A, et al. An adenovirus that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
5. Hallenbeck PL, Chang Y-N, Hay C, et al. Novel tumorspecific replication-competent adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1996;3:s19.
6. Rodriguez R, Schuur ER, Lim HY, et al. Prostate-attenuated replication-competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
7. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirusmediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
8. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56:5638-5646.
9. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for gene therapy. Hum Gene Ther. 1997;8:803-815.
10. Zhang J, Hu C, Geng Y, et al. Treatment of a human breast cancer xenograft with an adenovirus containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA. 1996;93:4513-4518.
11. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today. 1996:519-527.
12. Alemany R, Dai Y, Lou YC, et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J Virol Methods. 1997;68:147-159.
13. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through cre-lox recombination. J Virol. 1997;71:1842-1849.
14. Heise C, Sampson-Johannes A, Williams A, et al. Onyx-15, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3: 639-645.
15. Chen S-H, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996;56:3758-3762.